Patent · US Active

Solid form of (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-yl-quinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)-methanol

US11053233B2 · kind B2 · utility

0Cited by

3References

16Claims

0Family size

Assignee

Merck Patent GmbH · DE

Inventors

Michael Lange · Darmstadt, DE
Clemens Kuehn · Darmstadt, DE
Thomas Fuchss · Bensheim, DE
David Maillard · Coventry, GB
Marcel Breuning · Frankfurt am Main, DE
Marco Poma · Grosseto, IT
Edoardo Burini · Guidonia, IT

Key dates

Filing date	Mar 28, 2018
Grant date	Jul 6, 2021
Priority date	—
Expiry date	Mar 28, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07B2200/13
WIPO fieldChemical engineering
WIPO sectorChemistry

Abstract

An anhydrous disordered crystalline (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-yl-quinazolin-4-yl)-phenyl]-(6-methoxy-pyridazin-3-yl)-methanol can be used in pharmaceutical compositions.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.